Description: Cytarabine sulfate (MK-8242; SCH-900242), a pyrimidine nucleoside analog and an approved antumor drug, is an antimetabolic anticancer agent used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia, it also has antiviral and immunosuppressant properties. It is a DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells. Cytarabine (AraC) is phosphorylated into a triphosphate form (Ara-CTP) involving deoxycytidine kinase (dCK), which competes with dCTP for incorporation into DNA, and then blocks DNA synthesis by inhibiting the function of DNA and RNA polymerases. Its actions are specific for the S phase of the cell cycle.

References: Mol Pharm. 2004 Mar-Apr;1(2):112-6; Br J Cancer. 1988 Dec;58(6):730-3.

Related CAS#: 69-74-9 (HCl); 73532-83-9 (Fosteabine, Cytarabine ocfosfate; YNK 01; an oral prodrug analogue of cytarabine); 151823-14-2 [Sapacitabine, CS682; CYC682)]; 188181-42-2 [Elacytarabine (Synonyms: CP 4055)]; 332863-86-2 (MBC-11)

纯度：≥98%